Insight

Ahmad Ozair: Work from Adult Brain Tumor Consortium

Photo taken from Ahmad Ozair/X

Aug 10, 2024, 11:52

Ahmad Ozair: Work from Adult Brain Tumor Consortium

Ahmad Ozair, Postdoctoral Research Fellow in Neurosurgery at University of Maryland, shared a post on X:

“Out in this month’s issue of Clinical Cancer Research, our work from Adult Brain Tumor Consortium, led by Manmeet Ahluwalia– synthetic lethality by combining DNA alkylating agent (TMZ) with DNA repair inhibitor (TRC102) in BERT trial.”

Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT

Authors: Manmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, Xiaobu Ye, Sen Peng, Matthew Lee, Sanhita Rath, Harshil Dhruv, Yue Hao, Michael E Berens, Tobias Walbert, Matthias Holdhoff, Glenn J Lesser, Timothy F Cloughesy, Andrew E Sloan, Naoko Takebe, Marta Couce, David M Peereboom, Burt Nabors, Patrick Y Wen, Stuart A Grossman, and Lisa R Rogers.

TRC102 + TMZ

For more information.

Source: Ahmad Ozair/X

Adult Brain Tumor Consortium Ahmad Ozair cancer Clinical Cancer Research Jan Drappatz Lisa R Rogers Manmeet Ahluwalia Manmeet S. Ahluwalia OncoDaily Oncology Patrick Y Wen Stuart A Grossman

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial